The pharma manufacturing landscape in 2026 is more volatile than ever. Take part in this benchmarking study to see how your peers are responding. Rapidly changing geopolitics. Capacity constraints. Pricing pressure. Technology disruption. The challenges facing biopharma sponsors and CDMO
Join the Biotech CMC Bootcamp preview
Online Webinar / 19th March 2026
FDA hemorrhaging staff while promising to fast-track advanced modalities. BIOSECURE Act signed into law with five-year phase-out timelines. Tariffs creating 50% cost increases on manufacturing equipment. Most Favored Nation deals cutting prices. Cell and gene therapy facilities closing despite scientific
EXCLUSIVE DOWNLOAD Reshoring Pressure Meets Manufacturing Reality Download this report from External Manufacturing Leaders Boston for candid insights into how US Pharma and Biotech executives are navigating external manufacturing in 2026 In January 2026, senior external manufacturing executives from major pharmaceutical
Alliance for Regenerative Medicine’s State of the Industry briefing at JP Morgan Healthcare Conference signals cautious optimism backed by $11.1B in 2025 funding The cell and gene therapy (CGT) sector attracted $11.1 billion in investment across 216 financings in 2025—representing
“There are 437 active clinical trials in radiopharmaceuticals, and 100 companies developing them. If your logistics are not better, there is no other differentiator. You need to compete by experience.” When Kostja Paschalidis and his co-founders left their roles developing
As the pharmaceutical industry enters 2026, manufacturing leaders face a complex landscape shaped by geopolitical uncertainty, capacity constraints, and evolving therapeutic modalities. We asked senior executives across the sector what they see ahead—and their predictions reveal an industry bracing for
Kyriakos Kansos and George Ntortas of Fuliginous Management Consulting identify the trends that will define biopharma outsourcing over the next 12 months. In 2026 there are four forces are set to reshape the CDMO outsourcing landscape. 1. Modalities Face Capacity-Demand
Novo Nordisk received FDA approval Monday (22nd December) for oral Wegovy (semaglutide), marking the first oral GLP-1 receptor agonist cleared for obesity treatment. The Danish drugmaker plans a full US launch in early January 2026, with manufacturing underway at its
“When I walked into the tech transfer, we were a million dollars over budget, six months behind schedule, and struggling to make a single successful batch,” says Amy Gamber. Amy Gamber, Executive Director, Lifecycle Lead at Kyverna Therapeutics, specializes in
